This study sought to determine whether high intestinal cholesterol absorption represents a cardiovascular risk factor and to link ABCG8 and ABO variants to cardiovascular disease (CVD).
Background
Plant sterol-enriched functional foods are widely used for cholesterol lowering. Their regular intake yields a 2-fold increase in circulating plant sterol levels that equally represent markers of cholesterol absorption. Variants in ABCG8 and ABO have been associated with circulating plant sterol levels and CVD, thereby suggesting atherogenic effects of plant sterols or of cholesterol uptake.
Methods
The cholestanol-to-cholesterol ratio (CR) was used as an estimate of cholesterol absorption because it is independent of plant sterols. First, we investigated the associations of 6 single nucleotide polymorphisms in ABCG8 and ABO with CR in the LURIC (LUdwisghafen RIsk and Cardiovascular health study) and the YFS (Young Finns Study) cohorts. Second, we conducted a systematic review and meta-analysis to investigate whether CR might be related to CVD.
Results
In LURIC, the minor alleles of rs4245791 and rs4299376 and the major alleles of rs41360247, rs6576629, and rs4953023 of the ABCG8 gene and the minor allele of rs657152 of the ABO gene were significantly associated with higher CR. Consistent results were obtained for rs4245791, rs4299376, rs6576629, and rs4953023 in YFS. The meta-analysis, including 6 studies and 4,362 individuals, found that CR was significantly increased in individuals with CVD.
The American Heart Association has recommended plant sterolenriched foods (e.g., margarines) for cholesterol lowering (1) . Moreover, the European Heart Association and the European Atherosclerosis Society have mentioned plant sterol-enriched functional foods as cholesterol lowering agents in their guidelines for the management of dyslipidemia (2) . The regular intake of plant sterols reduces low-density lipoprotein (LDL) cholesterol by about 13 mg/dl (3) but also raises circulating plant sterols from about 1 mg/dl (4) by approximately 2-fold (5). Patients with sitosterolemia, a rare genetic disorder caused by mutations in the ATP-binding cassette transporters G5 and G8 (ABCG5 and ABCG8) (6) , have up to 50-fold increased circulating plant sterols and may develop early onset cardiovascular disease (CVD) (7) . Hence, it has been suggested that plant sterols are atherogenic (8) (9) (10) . These concerns have been reinforced by the detection of plant sterols in carotid atherosclerotic plaques (11) . In addition, plant sterol intake was related to increased plant sterol content in aortic valve cusps (12) . Two recent studies have confirmed that consumption of plant sterols as part of a dietary portfolio and as an adjunct to treatment with ezetimibe has favorable effects on the lipid profile (13, 14) . Nevertheless, in continuance of the long-lasting safety discussion, these studies also garnered critical comments (15, 16) . The debate was further fueled by a genome-wide association (GWA) study showing that common variants in the ABCG8 (major allele of rs41360247 and minor allele of rs4245791) and ABO (minor allele of rs657152) genes increased both circulating plant sterols and cardiovascular risk (17) . Correlations of variants in ABCG8 (minor allele of rs4299376) and ABO with CVD subsequently have been replicated in other large-scale GWA studies (18) (19) (20) . However, because circulating plant sterols are markers for cholesterol uptake (21) , the genetic data may also indicate adverse vascular effects of high cholesterol absorption.
The current study consisted of a genetic analysis and a meta-analysis; its purpose was to investigate whether high intestinal cholesterol absorption represents a cardiovascular risk factor and to link ABCG8 and AB0 variants to CVD. We used the ratio of circulating cholestanol-to-cholesterol to estimate levels of intestinal cholesterol absorption independently of plant sterol concentrations (22) .
Methods

Genetic analyses. STUDY DESIGN AND PARTICIPANTS.
Genetic association studies were performed in the LURIC (LUdwigshafen RIsk and Cardiovascular health study) and the YFS (Young Finns Study) (23, 24) .
LURIC is a cross-sectional and prospective German cohort study designed to investigate biochemical and genetic cardiovascular risk factors. A total of 3,316 participants referred for coronary angiography were recruited between July 1997 and January 2000 at the Ludwigshafen Heart Center (23). Measurements of lathosterol, cholestanol, campesterol, and sitosterol were completed in 1,257 LURIC participants who did not receive statins and did not have type 1 diabetes (25) . Individuals in this subgroup with available data on ABCG8 or ABO single nucleotide polymorphisms (SNPs) were included in the current analyses.
YFS is a Finnish population-based, 27-year follow-up study on the evolution of cardiovascular risk factors from childhood to adulthood (24) . The first cross-sectional study was conducted in 1980 at 5 centers and included 3,596 participants in the age groups of 3, 6, 9, 12, 15, and 18 years who were randomly chosen from the national population registry. In 2001, a total of 2,620 individuals, who were then aged 24 to 39 years, were studied. The sterol and lipid determinations used in the current analysis were taken from the year 2001 participants. Sterol and genetic data were available in 434 subjects.
Both studies were approved by the local ethical committees and performed according to the Declaration of Helsinki. Informed written consent was obtained from all participants (23, 24) . Diabetes mellitus was categorized according to the 2009 criteria of the American Diabetes Association (26) .
LABORATORY ANALYSES. All laboratory measurements were performed on fasting blood samples. In LURIC, cholesterol was measured with enzymatic reagents from WAKO (Neuss, Germany) on a WAKO 30 R or Olympus AU640 analyzer (Tokyo, Japan) (23). Lipoproteins were separated by a combined ultracentrifugation precipitation method (beta-quantification). Apolipoproteins B and E were measured by turbidimetry with reagents from Greiner (Flacht, Germany). Cholestanol (not a plant sterol; an intestinal absorption marker), campesterol and sitosterol (the 2 most abundant plant sterols; absorption markers), and lathosterol (cholesterol precursor; synthesis marker) were measured by using gas chromatography and mass spectrometry (25) . In YFS, total and high-density lipoprotein cholesterol were measured with enzymatic reagents from Olympus and Roche Diagnostics (Mannheim, Germany), respectively, on an Olympus AU400 analyzer. LDL cholesterol was calculated according to the Friedewald formula (27) . Apolipoprotein B was analyzed by using turbidimetry with reagents for Orion Diagnostica (Espoo, Finland). Noncholesterol sterols were measured with gas-liquid chromatography (28) .
GENOTYPING. Genomic DNA was prepared from peripheral blood in both cohorts. In LURIC, microarrays (Affymetrix 500k, Affymetrix 6.0, Illumina IBC 50k Cardiochip, and Illumina 200k Metabochip) were used to genotype the ABCG8 and ABO SNPs. In YFS, genotyping was performed by using the custom-built Illumina Human 670k BeadChip. SNPs were excluded in case of a low genotyping call rate (<0.95), Hardy-Weinberg-Equilibrium p value <10
À6
, minor allele frequency <0.01, heterozygosity, Sequenom fingerprint discrepancy, duplicated samples, or possible
(n ¼ 1,151), and rs4953023 (n ¼ 1,251) in the ABCG8 gene and rs657152 (n ¼ 1,202) in the ABO gene were available in LURIC. Rs4245791 (n ¼ 433), rs4299376 (n ¼ 434), rs6576629 (n ¼ 434), rs4953023 (n ¼ 434), and rs657152 (n ¼ 434) were available in YFS.
STATISTICAL ANALYSIS. Hardy-Weinberg equilibrium was examined with the chi-square test. R 2 was calculated by using the Web-tool according to Gaunt et al. (29) in both cohorts. We examined the distribution of the baseline clinical and biochemical characteristics across variants of the ABCG8 and ABO genes. Categorical data are presented as counts and percentages of subjects in each genotype group. Continuous data are presented as means AE SDs or medians with interquartile ranges. We used analysis of variance for continuous variables and chi-square tests for categorical variables to compare the distributions of variables across the genotypes. Additive genetic models were used for rs4245791, rs4299376, and rs657152. Because minor allele frequencies were <10% (resulting in very few study participants who were homozygous for the minor allele), we used dominant models for rs41360247, rs6576629, and rs4953023. We calculated ratios of the noncholesterol sterols to cholesterol to standardize for variation in cholesterol. Moreover, ratios of the absorption markers to lathosterol were computed to compare cholesterol absorption with de novo cholesterol synthesis. Data that were not normally distributed were transformed logarithmically. Analyzing data on 3 nonlinked groups of SNPs, we applied DunnSidák correction for 3 independent tests. We did not correct for the tested traits of interest because they were not independent. All statistical tests were 2-sided. Thus, p values <0.01695 were considered statistically significant. SPSS version 19.0 (IBM SPSS Statistics, IBM Corporation, Armonk, New York) and R version 2.11.1 (R Foundation for Statistical Computing, Vienna, Austria) statistical software packages were used in LURIC and YFS, respectively. Meta-analysis of cholestanol and CVD. DATA SOURCES, SEARCH STRATEGY, AND SELECTION CRITERIA. We systematically reviewed the published literature according to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) statement for the conduct of meta-analyses of epidemiological studies (30) . Relevant studies were identified by searching in MEDLINE via PubMed (from 1950 to January 2012). Search terms including key words and headings were ("cholestanol") and ("angiography" or "atherosclerosis" or "atherosclerotic plaque" or "CVD" or "cardiovascular mortality" or "cardiovascular event" or "cardiovascular risk" or "cerebrovascular disease" or "coronary artery disease" or "coronary calcium" or "coronary heart disease" or "mortality" or "myocardial infarction" or "peripheral arterial disease" or "stenosis" or "stroke", or "vascular"). We included studies with different research designs that reported on the association of absolute cholestanol concentration and/or cholestanol-to-cholesterol ratio with CVD. Because few studies were eligible and because the authors used heterogeneous endpoints related to CVD, we defined a composite primary endpoint. The endpoint comprised different definitions of CVD, including angiographically verified CVD, myocardial infarction, !50% carotid stenosis (verified by using Doppler analysis), coronary insufficiency, angina pectoris, cerebrovascular accident, transient ischemic attack, major cardiovascular events, and cardiovascular mortality.
DATA EXTRACTION. For each study identified, we obtained the original publications and extracted the following data into a spreadsheet: author, year of publication, country of origin, research design, major characteristics of the study population, descriptive statistics of cholestanol concentrations and/or cholestanol-to-cholesterol ratios (if provided for CVD cases and controls separately) or risk ratios (RRs) with respect to CVD based on cholestanol concentrations and/or cholestanol-to-cholesterol ratios (odds ratios, incidence rate ratios, or hazard ratios), the statistical method used for analysis, and the covariates adjusted included in multivariate modeling. We transformed absolute sterol concentrations into micrograms per deciliter and ratios to cholesterol into micrograms per milligram. For studies that reported circulating cholestanol and/or cholestanol to cholesterol ratio in CVD cases and controls separately, we calculated standardized mean differences (SMDs). For studies that reported RRs, we transformed the RRs to compare individuals in the top one-third versus those in the bottom one-third of the sterol distribution, as previously described (31) 
Cholesterol Uptake and Vascular Disease reported several estimates of RRs derived from multiple models using different sets of adjusting variables, we considered the estimate adjusted for most potential confounding variables (that have been collected in the particular study) as the gold standard estimate.
STATISTICAL ANALYSIS. We conducted two meta-analyses based on: 1) SMDs between CVD cases and controls; and 2) RRs. We examined for potential publication bias by using Egger's tests and Begg's tests as well as funnel plots. I 2 statistics and chi-square tests were used to investigate whether there was heterogeneity of estimates among studies. We calculated pooled summary estimates by using fixed effects (Mantel-Haenszel method) and random effects (DerSimonian and Laird model) meta-analysis techniques (32, 33) . Forest plots were used for visualizing study-specific estimates and the pooled fixed and random effects estimators. Statistical hypothesis testing was conducted 2-sided, and p values <0.05 were considered significant. Stata version 12.0 (Stata Corp., College Station, Texas) was used for analysis.
Results
Genetic studies. All SNPs were in Hardy-WeinbergEquilibrium in LURIC and YFS (all p > 0.15). The minor allele frequencies were 0.33 and 0.22 for rs4245791, 0.33 and 0.22 for rs4299376, 0.06 for rs41360247 (not available in YFS), 0.06 and 0.08 for rs6576629, 0.06 and 0.08 for rs4953023, and 0.40 and 0.44 for rs657152 in LURIC and YFS, respectively. Rs4245791 and rs4299376 showed high r 2 in both cohorts. Furthermore, rs41360247, rs6576629, and rs4953023 were strongly correlated (Online Tables 1 and 2) .
Sex, age, body mass index, and type 2 diabetes were not significantly related to the ABCG8 and ABO variants in either the LURIC or the YFS cohort (Tables 1 to 3; Online  Tables 3 to 5 ).
In LURIC, the major alleles of rs41360247 (Online Table 3 ), rs6576629 (Table 2) , and rs4953023 (Online Table 5 ) were associated with increased total cholesterol. There was also a trend toward an association between the minor allele of rs4245791 (Table 1 ) and increased total cholesterol. Furthermore, we observed a tendency toward higher LDL cholesterol in carriers of the minor alleles of rs4245791 (Table 1 ) and rs4299376 (Online Table 4 ) and of the major allele of rs6576629 ( Table 2 ). The major alleles of rs41360247 (Online Table 3 ), rs6576629 (Table 2) , and rs4953023 (Online Table 5 ) were associated with increased apolipoprotein B and E. A trend toward an association with apolipoprotein B was observed for rs4245791 ( Table 1) .
The minor alleles of rs4245791 (Table 1 ) and rs4299376 (Online Table 4 ) and the major alleles of rs41360247 (Online Table 3 ), rs6576629 (Table 2) , and rs4953023 (Online Table 5 ) were related to elevated levels of cholestanol, campesterol, and sitosterol; high absorption marker to cholesterol ratios; and high absorption marker to lathosterol ratios.
The minor allele of rs657152 (Table 3) was associated with high circulating campesterol and a high ratio of cholestanolto-cholesterol. A decrease in circulating lathosterol and the lathosterol to cholesterol ratio was observed for the minor alleles of rs4245791 (Table 1 ) and rs4299376 (Online Table 4 ). There was a trend toward a lower lathosterol to cholesterol ratio in carriers of the major alleles of rs6576629 (Table 2 ) and rs4953023 (Online Table 5 ).
In YFS, there was a trend for an association between the minor allele of rs657152 (Table 3 ) and increased LDL cholesterol concentration. The minor alleles of rs4245791 ( Table 1 ) and rs4299376 (Online Table 4 ) and the major alleles of rs6576629 (Table 2 ) and rs4953023 (Online Table 5 ) were associated with elevated cholestanol, campesterol, and sitosterol levels and high absorption marker to cholesterol ratios. In addition, rs4245791 (Table 1 ) and rs4299376 (Online Table 4 ) were associated with all ratios of the absorption markers to lathosterol. Likewise, rs6576629 (Table 2 ) and rs4953023 (Online Table 5 ) were associated with the campesterol and sitosterol to lathosterol ratios. Meta-analysis. Based on our search terms, we found 84 abstracts in MEDLINE; 9 publications were selected to be reviewed in full text (4, 25, (34) (35) (36) (37) (38) (39) (40) . Among these, 2 studies were excluded because of imprecise definitions of CVD (e.g., family history of coronary artery disease [35] and carotid intima media thickness [39] ), 1 study was excluded because the cross-sectional data on the relationship between cholestanol and CVD had been retrieved from another publication in the same cohort (34, 38) , and 1 study was excluded because neither data for calculating SMDs nor RRs were presented (40) . We included another study that did not show up in MEDLINE using our search term but was added based on personal knowledge (41). Thus, 6 studies (1 casecontrol study, 3 cohort studies, 1 cross sectional study, and 1 nested case-control study) with a total of 4,362 participants were included in the analyses. The studies had a sample size ranging from 109 to 2,440, and the participants ranged in age from 53.4 to 80.1 years. We used the fixed effects estimator because there was no significant heterogeneity among the studies.
Only 1 study reported on the relationship between uncorrected circulating cholestanol levels in CVD cases and controls, and it showed no association. The SMD in circulating cholestanol between cases and controls was 25 (95% confidence interval [CI]: À0.353 to 0.404; p ¼ 0.895) (34) . No study was retrieved that reported on RRs with regard to CVD based on uncorrected circulating cholestanol. Four studies were retrieved reporting on cholestanol-to-cholesterol ratios in CVD cases and controls separately (4, 34, 37, 40) . Among these, 3 reported higher cholestanol-to-cholesterol ratios in cases than in controls (4, 37, 40) , and 1 showed no difference (34) . There was neither publication bias (p ¼ 0.774) (Online Fig. 1 ) nor study heterogeneity (p ¼ 0.535). The pooled SMD between CVD cases and controls was 0.17 (95% CI: 0.09 to 0.25; p < 0.001) (Fig. 1) . Two studies reported on RRs with regard to CVD based on cholestanol-to-cholesterol ratios (25, 41) . Both studies showed that high cholestanol-to-cholesterol ratios were associated with increased cardiovascular risk. There was neither publication bias (p ¼ 0.317) (Online Fig. 2 ) nor study heterogeneity (p ¼ 0.483). The pooled RR for CVD comparing the highest versus the lowest tertile of the cholestanol-tocholesterol ratio was 1.72 (95% CI: 1.28 to 2.32; p < 0.001) (Fig. 2) . In short, a high cholestanol-to-cholesterol ratio was significantly related to increased risk for CVD.
Discussion
This study found that high rates of cholesterol absorption, as reflected by an elevated cholestanol-to-cholesterol ratio, are associated with risk alleles in ABCG8 and ABO and with present and future CVD. The LURIC and YFS data confirm previous GWA studies showing that risk alleles in ABCG8 and ABO are related to increased total and LDL cholesterol concentrations and the major protein components of LDL Silbernagel et al.
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Cholesterol Uptake and Vascular Disease (namely, apolipoproteins B and E) (42) (43) (44) . Our results for lathosterol suggest that high absorbers of cholesterol down-regulate endogenous cholesterol synthesis. However, this protective mechanism against hypercholesterolemia is obviously not strong enough. Elevated cholesterol absorption may thus result in a higher lifetime cholesterol burden and consequently increased plaque formation. High rates of cholesterol absorption, rather than elevated circulating plant sterol levels, seem to mediate the relationship of risk alleles in ABCG8 and ABO with CVD. An animal study also found that moderately decreased cholesterol absorption rates were associated with atheroprotection (45) . Moreover, a recent meta-analysis found no evidence of an association between circulating plant sterols and their ratios to cholesterol and CVD (46) . The discrepancy between the meta-analysis findings for cholestanol and for plant sterols may reflect the fact that plant sterols, unlike cholestanol, are also surrogate markers for dietary vegetable and fruit intake (47). We cannot rule out the possibility that high circulating cholestanol itself represents a cardiovascular risk factor. In cerebrotendinous xanthomatosis, a rare lipid storage disease caused by mutations in the gene encoding sterol 27-hydroxylase, circulating cholestanol is markedly increased (48) . Patients with this defect often present with dementia, ataxia, cataracts, and xanthomas in the tendons and in the nervous system. CVD is prevalent in about 10% of the patients with cerebrotendinous xanthomatosis. It would stand to reason that cholestanol directly promotes atherogenesis by accumulation in the atherosclerotic plaque. However, in an autopsy study, cholestanol represented just 2.8% of all the sterols in aortic deposits. Another hypothesis suggests that an alternative pathway of reverse cholesterol transport may be impaired in cerebrotendinous xanthomatosis and that high cholestanol would be indicative of such problems. To sum up, the intrinsic role of cholestanol in CVD remains to be elucidated and definitely merits further research. Nevertheless, the "absorption theory" seems robust in at least partly explaining the observations made in the genetic studies and in the Table 6 , and Online Figure 3 . Because high cholesterol absorption is associated with increased cardiovascular risk, inhibition of cholesterol uptake represents a promising target in the prevention and treatment of CVD. However, prospective clinical studies clearly demonstrating that the use of the cholesterol absorption inhibitor ezetimibe prevents cardiovascular complications are lacking. Whether plant sterol-enriched functional foods will reduce not only cholesterol absorption but also hard endpoints has not yet been investigated. At the same time, our data may dispel concerns that the modest increase in circulating plant sterol levels associated with their regular dietary intake could result in an adverse outcome. Study limitations. The major strength of the genetic analysis within LURIC is derived from the fact that it relies on 1 of the largest studies in which information on noncholesterol sterols and genetics have been collected simultaneously. Furthermore, we are able to replicate results obtained from LURIC in YFS, a cohort with contrasting patient characteristics. The meta-analysis is limited to a small number of observational studies, and these studies are heterogeneous with regard to their design and adjustment for potential confounding variables. Nevertheless, we have made the first attempt systematically to collate and analyze evidence from epidemiological studies that have investigated the relationships of cholestanol with CVD.
Conclusions
Our data support an atherogenic role for high intestinal cholesterol absorption. Harm caused by elevated cholesterol absorption rather than by high circulating plant sterols may, therefore, mediate the relationships of ABCG8 and ABO variants with CVD. 
